BRL03 / Biosyngen - LARVOL DELTA

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024 (PRNewswire) - "The highly anticipated 2024 European Society for Medical Oncology (ESMO)...Biosyngen...is presenting its groundbreaking 'Conditional Activation + Armor Enhancement' T-cell technology at this year's ESMO conference...the first patients have been enrolled in the Phase I trials for our other groundbreaking therapies, BST02 and BRL03, with completion of Phase I trials anticipated later this year....To overcome this technical challenge and balance safety with efficacy in solid tumor immune cell therapies, Biosyngen has developed the SUPER-T T cell safety optimization platform and created the Conditional Activation CAR-T cell BTRP003L. This technology allows CAR-T cells to activate only under hypoxic conditions typical of the tumor microenvironment (0.3% ~ 2.0% O2), while remaining inactive in normal tissues (3.4% ~ 6.8% O2)....Toxicology studies using the SUPER-T platform showed no weight loss or other adverse effects in mice injected with BTRP003L or BTRP011L,..."

Enrollment open • Preclinical • Trial completion date • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors (PRNewswire) - "Biosyngen Pte Ltd...announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and other advanced solid tumors. The approval granted to BRL03, the company's third first-in-class therapy, marks another breakthrough Biosyngen made in the CGT field."

IND • Gastric Cancer • Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer